ObsEva Expands Executive Team Hiring a Chief Commercial Officer
Geneva, Switzerland and Boston, MA - July 25, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced the appointment of a Chief Commercial Officer, Wim Souverijns, who will be based at the Company headquarters in Geneva, Switzerland.
Mr. Souverijns brings nearly 20 years of experience in the pharmaceutical industry and recently served as Corporate Vice President, Global Marketing, Hematology & Oncology within Celgene out of Summit, New Jersey. During his tenure at Celgene, Mr. Souverijns took on several strategic roles serving as Head of EMEA and later Global Marketing Excellence, as well as operational roles as General Manager for the Nordics and the UK & Ireland. Previously, Mr. Souverijns developed his pharmaceutical experience through various international assignments at PwC Consulting and in different market access leadership roles at Amgen, both in the European headquarters previously based in Luzern, Switzerland, as well as at the global level out of Thousand Oaks, California.
With the announcement of Wim Souverijns, ObsEva takes an important next step in the execution of its strategy building a leading women's reproductive health and pregnancy company focused on conditions where current treatment options are limited and significant unmet needs exist. With its pipeline of three potential best-in-class late stage-candidates developing according to plan and a potential go-to-market for nolasiban as early as 2020, the company strengthens its executive team with Wim Souverijns, a renowned and experienced commercial leader in the biopharmaceutical industry. Wim will be responsible for leveraging ObsEva's differentiated market position and building commercial capabilities needed to become a multi-product biopharmaceutical company.
Ernest Loumaye, CEO and Co-Founder of ObsEva said: "We are very excited to be welcoming Wim to ObsEva as we move forward after positive clinical trial results for nolasiban and linzagolix. As we enter this new chapter for the company, the addition of Wim's leadership and knowledge in the commercial field will be invaluable to prepare the company for the commercialisation of our novel, potential best-in-class women's reproductive health and pregnancy therapeutics."
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV", as well as on the SIX Swiss Exchange where it is trading under the ticker symbol "OBSN".
For more information, please visit .
###
For further information, please contact:
Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
Office
7 Mobile
Media Contact U.S.:
Jeanene Timberlake
RooneyPartners LLC
CEO Office Contact:
Shauna Dillon
Investor Contact:
Mario Corso
Senior Director, Investor Relations
Office
Mobile
Cautionary Note Regarding Forward Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva's current beliefs and expectations. These forward-looking statements include expectations regarding the advancement and commercial potential of our product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include the inherent uncertainties in the development and commercialization of therapies and clinical trials and other risks and uncertainties that are described in the Risk Factors section of ObsEva's Annual Report on Form 20-F for the year ended December 31, 2017, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva's website at . Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Attachment
